Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus

Virology

Volumn 396, Issue 2, 2010, Pages 329-338

  Rumyantsev, Alexander A ^a   Zhang, Zhen xi ^a   Gao, Qing sheng ^a   Moretti, Nicolas ^a   Brown, Nathan ^a   Kleanthous, Harold ^a   Delagrave, Simon ^a   Guirakhoo, Farshad ^a   Collett, Marc S ^a   Pugachev, Konstantin V ^a  

^a SANOFI PASTEUR   (France)

Author keywords

ChimeriVax; Flavivirus; Influenza; M2e epitope; NS1; Random insertion; Transposon; Vaccine vector

Indexed keywords

CHIMERIC PROTEIN; DIMER; IMMUNOGLOBULIN G2A; LIVE VACCINE; M2E PROTEIN; MONOCLONAL ANTIBODY; MONOMER; NONSTRUCTURAL PROTEIN 1; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIMERIZATION; FLAVIVIRUS; GENE INSERTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TRANSPOSON; VERO CELL; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CERCOPITHECUS AETHIOPS; ENCEPHALITIS VIRUS, JAPANESE; EPITOPES; FLAVIVIRUS; JAPANESE ENCEPHALITIS VACCINES; MICE; MUTAGENESIS, INSERTIONAL; VACCINES, SYNTHETIC; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES; WEST NILE VIRUS VACCINES;

FLAVIVIRUS; INFLUENZA A VIRUS; JAPANESE ENCEPHALITIS VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 70949095575     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.10.033     Document Type: Article

References (59)

1. Atasheva S., Gorchakov R., English R., Frolov I., and Frolova E. Development of Sindbis viruses encoding nsP2/GFP chimeric proteins and their application for studying nsP2 functioning. J. Virol. 81 (2007) 5046-5057
2. Barba-Spaeth G., Longman R.S., Albert M.L., and Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 202 (2005) 1179-1184
3. Bonaldo M.C., Garratt R.C., Caufour P.S., Freire M.S., Rodrigues M.M., Nussenzweig R.S., and Galler R. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J. Mol. Biol. 315 (2002) 873-885
4. Bonaldo M.C., Garratt R.C., Freire M.S., and Galler R. Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein. Cell Biochem. Biophys. 44 (2006) 313-324
5. Brandt W.E., Chiewslip D., Harris D.L., and Russell P.K. Partial purification and characterization of a dengue virus soluble complement-fixing antigen. J. Immunol. 105 (1970) 1565-1568
6. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., and Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345 (2006) 299-304
7. Brune W., Ménard C., Hobom U., Odenbreit S., Messerle M., and Koszinowski U.H. Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis. Nat. Biotechnol. 17 (1999) 360-364
8. Bui H.H., Peters B., Assarsson E., Mbawuike I., and Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 246-251
9. Burke D.S., and Monath T.P. Flaviviruses. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 4th ed (2001), Lippincott Williams and Wilkins, Philadelphia 1043-1126
10. Chambers T.J., Nestorowicz A., Mason P.W., and Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73 (1999) 3095-3101
11. Chung K.M., Liszewski M.K., Nybakken G., Davis A.E., Townsend R.R., Fremont D.H., Atkinson J.P., and Diamond M.S. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19111-19116
12. Clark D.C., Lobigs M., Lee E., Howard M.J., Clark K., Blitvich B.J., and Hall R.A. In situ reactions of monoclonal antibodies with a viable mutant of Murray Valley encephalitis virus reveal an absence of dimeric NS1 protein. J. Gen. Virol. 88 (2007) 1175-1183
13. Crooks A.J., Lee J.M., Easterbrook L.M., Timofeev A.V., and Stephenson J.R. The NS1 protein of tick-borne encephalitis virus forms multimeric species upon secretion from the host cell. J. Gen. Virol. 75 (1994) 3453-3460
14. Das S.C., and Pattnaik A.K. Role of the hypervariable hinge region of phosphoprotein P of vesicular stomatitis virus in viral RNA synthesis and assembly of infectious virus particles. J. Virol. 79 (2005) 8101-8112
15. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londoño-Arcila P., Fiers W., and Saelens X. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26 (2008) 6503-6507
16. Fiers W., De Filette M., Birkett A., Neirynck S., and Min Jou W. A "universal" human influenza A vaccine. Virus Res. 103 (2004) 173-176
17. Flamand M., Megret F., Mathieu M., Lepault J., Rey F.A., and Deubel V. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J. Virol. (1999) 6104-6110
18. Frolov I., Garmashova N., Atasheva S., and Frolova E.I. Random insertion mutagenesis of Sindbis virus nsP2 and selection of variants incapable of downregulating cellular transcription. J. Virol. 83 18 (2009) 9031-9044
19. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., Shiver J.W., Liang X., and Joyce J.G. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27 (2009) 1440-1447
20. Gehrke R., Heinz F.X., Davis N.L., and Mandl C.W. Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon. J. Gen. Virol. 86 (2005) 1045-1053
21. Gubler D., Kuno G., and Markoff L. Flaviviruses. In: Knipe D.M., Howley P.M., Griffin D.E., Martin M.A., Lamb R.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed (2007), Wolters Kluwer, Lippincott Williams and Wilkins, Philadelphia 1153-1252
22. Guirakhoo F., Zhang Z.X., Chambers T.J., Delagrave S., Arroyo J., Barrett A.D., and Monath T.P. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257 (1999) 363-372
23. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Soike K., Ratterree M., and Monath T.P. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75 (2001) 7290-7304
24. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Draper K., and Monath T.P. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298 (2002) 146-159
25. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., Yoksan S., Duan X., Ermak T.H., Kanesa-Thasan N., Bedford P., Lang J., Quentin-Millet M.J., and Monath T.P. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2 (2006) 60-67
26. Hall R.A., Khromykh A.A., Mackenzie J.M., Scherret J.H., Khromykh T.I., and Mackenzie J.S. Loss of dimerisation of the nonstructural protein NS1 of Kunjin virus delays viral replication and reduces virulence in mice, but still allows secretion of NS1. Virology 264 (1999) 66-75
27. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., Tang J., McDonald W., Song L., Evans R.K., Umlauf S., Tussey L., and Powell T.J. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26 (2008) 201-214
28. Jegerlehner A., Schmitz N., Storni T., and Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172 (2004) 5598-5605
29. Jones C.T., Patkar C.G., and Kuhn R.J. Construction and applications of yellow fever virus replicons. Virology 331 (2005) 247-259
30. Kleanthous, H., Miller, C., Oros, L., 2002. Chimeric flavivirus vectors. US patent 7569383.
31. Lindenbach B.D., and Rice C.M. Genetic interaction of flavivirus nonstructural protein NS1 and NS4A as a determinant of replicase function. J. Virol. 73 (1999) 4611-4621
32. Lindenbach B.D., and Rice C.M. Molecular biology of flaviviruses. Adv. Virus Res. 59 (2003) 23-61
33. Lindenbach B.D., Thiel H.-J., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Martin M.A., Lamb R.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed (2007), Wolters Kluwer, Lippincott Williams and Wilkins, Philadelphia 1101-1152
34. McAllister A., Arbetman A.E., Mandl S., Peña-Rossi C., and Andino R. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J. Virol. 74 (2000) 9197-9205
35. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., Blum P., Woodward S., McCarthy K., Mathis D., Johnson C., and Bedford P. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188 (2003) 1213-1230
36. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., McCarthy K., Johnson C., Ermak T., Shin S., Arroyo J., Guirakhoo F., Kennedy J.S., Ennis F.A., Green S., and Bedford P. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6694-6699
37. Monath T.P., Cetron M.S., and Teuwen D.E. Yellow fever vaccine. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed (2008), Saunders Elsevier, Philadelphia 959-1055
38. Moradpour D., Evans M.J., Gosert R., Yuan Z., Blum H.E., Goff S.P., Lindenbach B.D., and Rice C.M. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 78 (2004) 7400-7409
39. Muylaert I.R., Galler R., and Rice C.M. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J. Virol. 71 (1997) 291-298
40. Navaratnarajah C.K., and Kuhn R.J. Functional characterization of the Sindbis virus E2 glycoprotein by transposon linker-insertion mutagenesis. Virology 363 (2007) 134-147
41. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5 (1999) 1157-1163
42. Oceguera III L.F., Patiris P.J., Chiles R.E., Busch M.P., Tobler L.H., and Hanson C.V. Flavivirus serology by Western blot analysis. Am. J. Trop. Med. Hyg. 77 (2007) 159-163
43. Olson M.R., and Varga S.M. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert. Rev. Vaccines 7 (2008) 1239-1255
44. Palmer D.R., Fernandez S., Bisbing J., Peachman K.K., Rao M., Barvir D., Gunther V., Burgess T., Kohno Y., Padmanabhan R., and Sun W. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J. Gen. Virol. 88 (2007) 148-156
45. Patiris P.J., Oceguera III L.F., Peck G.W., Chiles R.E., Reisen W.K., and Hanson C.V. Serologic diagnosis of West Nile and St. Louis encephalitis virus infections in domestic chickens. Am. J. Trop. Med. Hyg. 78 (2008) 434-441
46. Pijlman G.P., Suhrbier A., and Khromykh A.A. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin. Biol. Ther. 6 (2006) 135-145
47. Pugachev K.V., Guirakhoo F., Trent D.W., and Monath T.P. Traditional and novel approaches to flavivirus vaccines. Int. J. Parasitol. 33 (2003) 567-582
48. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., and Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203 (2006) 413-424
49. Rang A., Heider H., Ulrich R., and Krüger D.H. A novel method for cloning of non-cytolytic viruses. J. Virol. Methods 135 (2006) 26-31
50. Risatti G.R., Holinka L.G., Lu Z., Kutish G.F., Tulman E.R., French R.A., Sur J.H., Rock D.L., and Borca M.V. Mutation of E1 glycoprotein of classical swine fever virus affects viral virulence in swine. Virology 343 (2005) 116-127
51. Rumyantsev A.A., Murphy B.R., and Pletnev A.G. A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J. Virol. 80 (2006) 1427-1439
52. Schlesinger J.J., Brandriss M.W., and Walsh E.E. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J. Immunol. 135 (1985) 2805-2809
53. Schlesinger J.J., Brandriss M.W., and Walsh E.E. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68 (1987) 853-857
54. Schotsaert M., De Filette M., Fiers W., and Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev.Vaccines 8 (2009) 499-508
55. Tao D., Barba-Spaeth G., Rai U., Nussenzweig V., Rice C.M., and Nussenzweig R.S. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J. Exp. Med. 201 (2005) 201-209
56. Timofeev A.V., Butenko V.M., and Stephenson J.R. Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes 28 (2004) 85-97
57. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., and Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64 (1990) 1375-1377
58. Wilson J.R., de Sessions P.F., Leon M.A., and Scholle F. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J. Virol. 82 (2008) 8262-8271
59. Winkler G., Randolph V.B., Cleaves G.R., Ryan T.E., and Stollar V. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 162 (1988) 187-196